Neuronetics, Inc.
About Neuronetics, Inc.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $149.2M
- Net income
- -$39.0M
- Total assets
- $141.6M
- Market cap
- $89.8M
- Gross margin
- 72.3%
- Operating margin
- -46.2%
- Net margin
- -58.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $74.9M
- Cost of revenue
- $20.7M
- Gross profit
- $54.2M
- Operating expenses
- $88.7M
- Operating income
- -$34.6M
- Net income
- -$43.7M
- EPS (basic)
- $-1.38
- EPS (diluted)
- $-1.38
Balance sheet
- Total assets
- $140.9M
- Current assets
- $58.1M
- Total liabilities
- $109.1M
- Current liabilities
- $31.3M
- Shareholders’ equity
- $31.8M
Cash flow
- Operating cash flow
- -$31.0M
- Investing cash flow
- -$2.4M
- Financing cash flow
- -$6.8M
- Net cash flow
- -$40.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $89.8M
- EPS (diluted)
- $-1.38
- Shares outstanding
- 70.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.0M in FY2025.
- Revenue grew 52% from FY2020 to FY2024.
- Gross margin of 72.3%, net margin -58.4%.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Neuronetics, Inc..
Write a review
News about Neuronetics, Inc.
News & sentiment via Polygon.io
